A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of The Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee

Trial Profile

A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of The Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Tanezumab (Primary)
  • Indications Musculoskeletal pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Aug 2017 Planned End Date changed from 23 Oct 2018 to 30 Oct 2018.
    • 13 Jun 2017 According to a Pfizer media release, results from this study are expected in 2018.
    • 31 May 2017 Planned End Date changed from 12 Aug 2018 to 23 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top